Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
by
,
Dana M. Hartl
1,*, 
Joanne Guerlain
1,
Ingrid Breuskin
1,
Julien Hadoux
2,
Eric Baudin
2,
Abir Al Ghuzlan
3,
Marie Terroir-Cassou-Mounat
2,
Livia Lamartina
2 and
Sophie Leboulleux
2 1
Department of Surgery, Anesthesia and Interventional Medicine Gustave Roussy, 94805 Villejuif, France
2
Department of Nuclear Medicine and Endocrine Oncology, Anesthesia and Interventional Medicine Gustave Roussy, 94805 Villejuif, France
3
Department of Biology and Pathology, Anesthesia and Interventional Medicine Gustave Roussy, 94805 Villejuif, France
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(11), 3282; https://doi.org/10.3390/cancers12113282
Submission received: 1 October 2020
/
Revised: 2 November 2020
/
Accepted: 4 November 2020
/
Published: 6 November 2020
(This article belongs to the Special Issue 2020 Update on the Management of Thyroid Cancer)
Simple Summary
Total thyroidectomy used to be recommended for all thyroid cancers. We now know that some thyroid cancers have a relatively low risk of recurrence. Today, for some of these cancers, depending on the type of tumor, its’ size and other tumor characteristics, a thyroid lobectomy (or hemithyroidectomy) can be performed without increasing the patient’s risk of cancer recurrence. Thyroid lobectomy has the advantages of having less risk of surgical complications and a less frequent need for thyroid hormone replacement therapy. This approach is not optimal for all thyroid cancers, however, and careful tumor and patient selection are necessary. This review explains the rationale and criteria for patient selection for thyroid lobectomy for selected thyroid cancers.
Abstract
Many recent publications and guidelines have promoted a “more is less” approach in terms of treatment for low to intermediate risk differentiated thyroid cancer (DTC), which comprise the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up. Following this approach, thyroid lobectomy has been proposed as a means of decreasing short- and long-term postoperative morbidity while maintaining an excellent prognosis for tumors meeting specific macroscopic and microscopic criteria. This article will examine the pros and cons of thyroid lobectomy for low to intermediate risk cancers and discuss, in detail, criteria for patient selection and oncological outcomes.
Keywords:
thyroid cancer; lobectomy; thyroidectomy; prognosis; risk stratification
